---
title: "中國科創產業投資發佈中期業績 股東應占溢利 510.7 萬港元 同比扭虧為盈"
description: "智通財經 APP 訊，中國科創產業投資發佈截至 2025 年 6 月 30 日止 6 個月業績，該集團期內取得收益 6.92 萬港元，同比減少 16.31%;公司擁有人應占溢利 510.7 萬港元，同比扭虧為盈;每股基本盈利 0.018 港元。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/254981297.md"
published_at: "2025-08-28T10:50:14.000Z"
---

# 中國科創產業投資發佈中期業績 股東應占溢利 510.7 萬港元 同比扭虧為盈

> 智通財經 APP 訊，中國科創產業投資發佈截至 2025 年 6 月 30 日止 6 個月業績，該集團期內取得收益 6.92 萬港元，同比減少 16.31%;公司擁有人應占溢利 510.7 萬港元，同比扭虧為盈;每股基本盈利 0.018 港元。

智通財經 APP 訊，中國科創產業投資 (00339) 發佈截至 2025 年 6 月 30 日止 6 個月業績，該集團期內取得收益 6.92 萬港元，同比減少 16.31%;公司擁有人應占溢利 510.7 萬港元，同比扭虧為盈;每股基本盈利 0.018 港元。

### Related Stocks

- [00339.HK - 中國科創產業投資](https://longbridge.com/zh-HK/quote/00339.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| China SciTech Industrial Investment Group Ltd announces estimated NAV per share of HK0285 as at 31 January 2026 | China Sci-Tech Industrial Investment Group Ltd has estimated its unaudited consolidated net asset value (NAV) per share  | [Link](https://longbridge.com/zh-HK/news/275429492.md) |
| China Isotope & Radiation Warns of Up to 25% Lower 2025 Profit | China Isotope & Radiation Warns of Up to 25% Lower 2025 Profit | [Link](https://longbridge.com/zh-HK/news/275759475.md) |
| Obesity Raises Risk Of Hospitalization Or Death From Infections By 70%, Study Finds | A new study reveals that individuals with obesity are 70% more likely to be hospitalized or die from infections. Analyzi | [Link](https://longbridge.com/zh-HK/news/275645321.md) |
| UN agency begins clearing huge Gaza City waste dump as health risks mount | The UN Development Programme has begun clearing a large garbage dump in Gaza City, which poses significant health and en | [Link](https://longbridge.com/zh-HK/news/275635642.md) |
| Cause of death for Catherine O'Hara identified | Catherine O'Hara's cause of death has been identified as pulmonary embolism, with rectal cancer as an underlying factor. | [Link](https://longbridge.com/zh-HK/news/275452756.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。